Globally, Pfizer has estimated it could have 50 million doses available by year's end. Photo / APNot far behind is competitor Moderna Inc.'s Covid-19 vaccine. "We don't know what that vote's going to be," said former FDA vaccine chief Norman Baylor. EMERGENCY USE ISN'T THE SAME AS FULL APPROVALIf there's an emergency green light, "that vaccine is still deemed investigational. A decision on Pfizer-BioNTech's vaccine won't affect other Covid-19 vaccine candidates in the pipeline, which will be judged separately.

Source: New Zealand Herald November 20, 2020 18:00 UTC